Cat. No. | Product name | CAS No. |
DC60636 |
Acid-degradable Cationic Lipid (ADC)
Featured
Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
|
DC60637 |
BI-9508
Featured
BI-9508 is a potent and selective, brain-penetrant GPR88 agonist with EC50 of 47 nM. |
|
DC66614 |
Vc-seco-duba
Featured
Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco. |
1345681-58-4 |
DC66615 |
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br
Featured
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br is an ADC linker that can be used to synthesize ABBV-154, ABBV-927, ABBV-368 or their analogs. |
2344809-82-9 |
DC66616 |
Sulfo-PDBA-DM4
Featured
Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. |
1461704-01-7 |
DC66617 |
Mal-amido-PEG6-NHS ester
Featured
Mal-amido-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. |
1137109-21-7 |
DC66618 | 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid DIEA Salt Featured | 1193111-38-4 |
DC66619 |
Val-Ala-PAB
Featured
Val-Ala-PAB is a cleavable ADC linker that can be used for ADCs synthesis. |
1343476-44-7 |
DC66620 |
Fomc-Gly-Gly-Phe-Gly-OH
Featured
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit. |
1817857-75-2 |
DC66621 | Fmoc-GGFL-OH Featured | |
DC66622 |
Licaminlimab
Featured
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation. |
|
DC66623 |
Gremubamab
Featured
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. |
1800381-36-5 |
DC66624 |
Nirsevimab
Featured
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections. |
1989556-22-0 |
DC66625 |
Aselizumab
Featured
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma. |
395639-53-9 |
DC66626 |
Raxibacumab
Featured
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research. |
565451-13-0 |
DC66627 |
Afelimomab
Featured
Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis. |
156227-98-4 |
DC66628 | Anti-158P1D7 Reference Antibody Featured | |
DC66629 | Numab patent anti-HSA Featured | |
DC66630 |
Birtamimab
Featured
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis. |
1608108-91-3 |
DC66631 |
Mirzotamab
Featured
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC). |
2229859-11-2 |
DC66632 |
Cantuzumab
Featured
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493). |
1204740-23-7 |
DC66633 | VLST-002 Featured |